We believe Cochrane is a key source of scientific evidence on diagnostic and therapeutic medical issues. The very recent expulsion of Peter Gøtzsche from the Cochrane Board and subsequent retirement of four Board members have great impact on the existence of this organisation. Beside issues mentioned by other authors1-3 we believe this crisis is a good opportunity to fix a big problem raised by Peter Gøtzsche and others about Cochrane’s conflict of interest policy.
La revue Prescrire is glad to host the next General Assembly in Paris (France). This will be a wonderful opportunity for Prescrire staff to meet colleagues from around the world, and for you to visit our office and the ISDB library, maintained by Minata Traoré at Prescrire since the creation of the society.
In June 2017 ISDB Committee members and other bulletins interested, participated in a workshop on clinical study reports (CSRs). This two day workshop was organized by the Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (Institute for Quality and Efficiency in Health Care, IQWIG) in Cologne, Germany. Beate Wieseler and her colleagues lectured about the framework of these CSRs and we could also practice what we had learned. The participants were very enthusiastic about this experience and the Committee discussed how we could further develop our knowledge. Interestingly, the Cochrane Collaboration was also working on this topic and the Committee and interested members gave input to their proposal on the guidance for including CSR’s in their reviews. On the Cochrane Collaboration’s website the following information was shared (http://community.cochrane.org/ news/request-comments-draftinterim-guidance-how-decidewhether-incorporate-clinical-studyreports-and-other-regulatorydocuments-cochrane-reviews).
Nuria Homedes We have been working hard. Two years ago, we divided Bulletin Farmacos in four bulletins. Due to the large amount of information that is emerging and the interests of our Spanish readership, one of the bulletins has been dedicated to Ethics and Clinical trials. The other bulletins are devoted to Pharmacovigilance and Appropriate use, Access and Economics, Regulatory Agencies and Policies. Consequently, we have increased the number of translations into Spanish from English and French sources.